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ABSTRACT 
Chronic hyperglycaemia is a peculiar feature of diabetes mellitus (DM). Sequential metabolic 
abnormalities accompanying glucotoxicity are some of its implications. Glucotoxicity most 
likely corresponds to the vascular intricacy and metabolic alterations, such as increased 
oxidation of free fatty acids and reduced glucose oxidation. More than half of those with 
diabetes also develop cardiac abnormalities due to unknown causes, posing a major threat to 
the currently available marketed preparations which are being used for treating these cardiac 
complications. Even though impairment in cardiac functioning is the principal cause of death 
in individuals with type 2 diabetes (T2D), reducing plasma glucose levels has little effect on 
cardiovascular disease (CVD) risk. In vitro and in vivo studies have demonstrated that 
inhibitors of sodium glucose transporter (SGLT) represent a putative therapeutic intervention 
for these pathological conditions. Several clinical trials have reported the efficacy of SGLT 
inhibitors as a novel and potent anti-diabetic agent which along with its anti-hyperglycaemic 
activity possesses the potential of effectively treating its associated cardiac abnormalities. 
Thus, hereby, the present review highlights the role of SGLT inhibitors as a successful drug 
candidate for correcting the shifts in deregulation of cardiac energy substrate metabolism 
together with its role in treating diabetes related cardiac perturbations. 
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INTRODUCTION 
Diabetes mellitus (DM) is a chronic metabolic disorder characterised by progressive 
hyperglycaemia and sequential metabolic abnormalities accompanying glucotoxicity [1]. 
Hyperglycaemia in type1 diabetes (T1D) pertains to the absolute loss of pancreatic β cells, 
whereas in T2D, hyperglycaemia is an indicative of an insulin resistant state together with the 
abnormalities in an insulin production and its secretion, including various endocrinopathies 
contributing in this heterogeneous disorder [2]. An insulin resistant state in T2D is followed 
by a concomitant hyperglycaemia, hypertension, dyslipidemia, pro-thrombotic factors, and 
pro-inflammatory state. All of these factors are interrelated in the pathogenesis of cardiac 
complications and are considered as a significant paramount for an increased risk of cardiac 
abnormalities [1,2]. Glucotoxicity most likely corresponds to the vascular intricacy attending 
DM. Micro-vascular diseases are stratified by the changes in vessel size, development of 
diabetes associated nephropathy, neuropathy, retinopathy and onset of premature macro-
vascular or cardiovascular (CV) complications [1]. 
On an average, 450 million people were affected by diabetes in year 2015 and this 
number has been projected to escalate to 642 million by the end of year 2040. Countries with 
low national per capita income/developing countries are at increased risk of having CV 
mortality due to diabetes related cardiac abnormalities [3]. Multiple trials including Diabetes 
Control and Complications Trial Research Group and UK Prospective Diabetes Study 
(UKPDS) came to an agreement that micro-vascular changes can be improved by monitoring 
the glycaemic control [4,5]. However, macro-vascular changes convey a potential risk for the 
progression of cardiac abnormalities [1]. Obese/overweight individuals or individuals with 
concomitant hyperglycaemia, hypertension, dyslipidemia, pathogenic and pro-inflammatory 
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beyond hyperglycaemia that are commonly presentable in majority of the T2D patients, a 
multi-factorial approach for combating these CV risk contributors needs to be highlighted. 
Currently available drugs for the treatment of diabetes are potent glucose lowering agents, 
capable of improving accompanying cardio-metabolic abnormalities but their chronic use for 
sustained glycaemic control, limits their efficacy [8]. Recently, up-regulation of SGLT has 
been implicated in causing glucose dysregulation and alterations in cardiac energy substrate 
metabolism in diabetic patients [9-12]. In hyperglycaemic conditions, glucose transport 
through SGLT is also associated with the activation of NADPH oxidase (NOX2), production 
of reactive oxygen species (ROS), and cell death of cardiomyocytes (13,14). 
Currently, much attention has been laid on the role of SGLT1/SGLT2 inhibitors for 
improving glycaemic control by reducing intestinal and renal absorption of glucose and by 
promoting excretion of glucose in urine [15]. SGLT1 is expressed in heart tissue of several 
species including various other organs. Increased cardiac glucose uptake and SGLT1 
expression has been reported in diabetic cardiomyopathy [16]. Therefore, aforementioned 
facts clearly indicate that inhibition of SGLT could be the newer therapeutic strategy for the 
management of diabetes and its associated cardiomyopathy. The present review discusses 
about the newer therapeutic approach aimed at improving hyperglycaemia associated 
complications by altering the function of sodium glucose transporters (SGLT) in heart and 
kidney. 
 
MECHANISMS INVOLVED IN DIABETES INDUCED CARDIAC 
COMPLICATIONS 
Chronic diabetes is a cluster of numerous cardiac abnormalities such as cardiac dysfunction, 
ischemia/reperfusion (I/R) injury, cardiomyopathy and microangiopathy [17,18]. Alterations 
in lipid profile, pancreatic insulin insufficiency, increased glycaemic index and sedentary 
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the precise mechanism and pathways involved in the development and worsening of cardiac 
dysfunction in hyperglycaemic subjects are not clearly understood [19]. However, ROS 
generation and alterations in cardiac energy substrate metabolism could be the probable 
mechanisms responsible for diabetes induced cardiac abnormalities. 
 
The reactive oxygen species (ROS) theory 
Hyperglycaemic condition is well correlated with oxidative damage and insulin resistance, 
which occurs through oxidative phosphorylation (OXPHOS) of glucose in mitochondria. 
OXPHOS of glucose is related with the generation of free radicals such as nitrite, hydroxyl 
ions and superoxide anion [20]. Oxidative damage occurs at cellular level causing direct 
damage to proteins and mitoDNA causing modulations in normal physiological processes 
[21, 22]. For instance, elevated oxidative load is linked with the down-regulation of nitric 
oxide level causing impairment in the functioning of endothelium, ultimately heading 
towards vascular dysfunction and CV abnormalities [23-25]. Role of oxidative stress in 
modulating various intracellular signalling pathways has been well recognized [26]. In insulin 
resistant state, translocation of glucose transporter 1 (GLUT1) from intracellular 
compartments towards the plasma membrane is significantly decreased. However, under the 
same condition, SGLT1 gets expressed in the sarcolemma membrane where it co-localizes 
with the sodium potassium ATPase. An age-dependent increase in the cardiac SGLT1 
expression is reported in mice models, although the underlying mechanism behind this 
increase is still unknown. SGLT1 up-regulation is also related with the glucotoxicity and 
insulin resistant state in T2D (27). Figure 1 gives a brief idea about the role of SGLT1 
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Cardiac energy substrate metabolism 
Insulin sensitive/ insulin resistant mechanism are necessary for proper cardiac functioning. 
Studies carried out by Belke et al., in cardiomyocyte selective insulin receptor knockout mice 
demonstrates that proper insulin signalling is of utmost relevance for maintenance and 
maturation of contractile phenotype of cardiomyocytes.  Results of their study indicates that 
in cardiomyocytes derived from insulin signalling deficient mice there exists a shift in cardiac 
energy substrate metabolism which can be characterized by decreased fatty acid oxidation 
and elevated glucoxidation [28]. The observed shift in substrate metabolism is paradoxically 
the reversed change as evident in diabetes, where fatty acids are major cardiac fuel compared 
to glucose [29]. Insulin-dependent glucose uptake at cellular level is primarily carried out by 
glucose transporters, which facilitates the transport of glucose from intracellular compartment 
to the cell membrane [30]. However, SGLT are another class of transporters which are 
involved in the renal, intestinal and cardiac absorption of glucose [31]. 
 
RENAL AND INTESTINAL GLUCOSE ABSORPTION: ROLE OF SODIUM 
GLUCOSE TRANSPORTERS 
Approximately 160-180 g of glucose is filtered on the daily basis by glomeruli of kidneys in 
normo-glycaemic individuals. Most of the filtered glucose is reabsorbed by the proximal 
tubules [14, 32-35], however in diabetic condition, amount of filtered glucose exceeds the 
maximal threshold for renal glucose absorption such that the excess glucose is excreted out in 
urine [36-38]. Between the early 1980’s and 1995, transport studies carried out on membrane 
vesicles and gene expression studies in isolated proximal tubules of rat and rabbit revealed 
that most of the glucose uptake is mediated by the two SGLT namely (i) high affinity/low 
capacity SGLT1 (SLC5A1) (K0.5 of 0.4mM for glucose and 3 mM for sodium) and (ii) low 
affinity/high capacity SGLT2 (SLC5A2) (K0.5 of about 2∙0 mM for glucose and about 0∙1 
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accumulating glucose within the cells. SGLT are capable of initiating several intracellular 
events as sodium glucose co-transport is coupled with the membrane depolarization. SGLT1 
also act as a rate limiting factor for glucose absorption [34,40,41]. Among both the SGLT 
isoforms, SGLT2 is responsible for the maximum renal glucose absorption (approximately 
90%) in the segment 1 (S1) region of the proximal tubule while the SGLT1 facilitates the 
absorption of intestinal glucose, contributing only 10% of the total renal glucose absorption 
in the S3 segment of distal proximal tubule. SGLT2 inhibitors exert its anti-hyperglycaemic 
activity through increased renal excretion of glucose in urine posing a minimal risk for 
hypoglycaemia. Increased volume depletion due to elevated glycosuria also helps in reducing 
blood pressure and promoting weight loss [39]. 
 
SGLT1transporter is predominantly expressed in gut, heart and lungs. SGLT1 is the 
principal transporter present in the enterocytes lining intestinal villi, these transporters 
account for maximal glucose absorption in the intestine. Transport of glucose across the 
brush border of apical membrane is driven by electrogenic gradient established by sodium 
potassium ATPase pump [42,43]. Mutations in the SGLT1 genes (SLC5A1) or defects in 
SGLT1 trafficking are responsible for causing glucose galactose malabsorption, an autosomal 
recessive disease characterised by severe diarrhoea and dehydration [39,44]. mRNA 
expression analyses have conferred its localization in several other organs as well, such as 
brain, skeletal muscle, lung, gall bladder, trachea, liver, uterus, testis, colon, rectum, brain, 
blood vessels, stomach, mesenteric adipose tissue, breast, pancreatic alpha-cells including 
heart. Table 1 enlists the different organs where SGLT1 is expressed in humans and rats [34, 
43, 45-47]. Expression of SGLT1 has also been reported in rats and humans myocyte and 
sarcolemma of heart. In diabetes, improved capacity of cardiac glucose uptake by SGLT1 
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playing a significant role in sustained hyperglycaemia and worsening of cardiac functions 
[48-49]. Figure 1 gives the brief representation of the role of SGLT inhibitors in progression 
of diabetic cardiomyopathy. 
 
DIABETIC CARDIOMYOPATHY AND SGLT1 
The term diabetic cardiomyopathy was coined by Rubler et al. in 1972. Clinically, it is 
defined as the structural and functional changes of myocardium occurring in diabetic 
individuals even in the absence of coronary artery disease and hypertension [51]. Compared 
to the healthy individuals, individuals with diabetic cardiomyopathy are more vulnerable 
towards the increased risk of heart failure. Numerous reports suggest that ROS has been 
implicated in the progression and development of diabetic cardiomyopathy. ROS deteriorates 
the normal cardiac functioning by causing direct damage to proteins, initiating programmed 
cell death and altering several signal transduction pathways [50,52]. 
Association of high glucose and activation NOX2 was clearly demonstrated by 
Balteau and his colleagues in their in-vitro study conducted on primary cultured rat 
cardiomyocytes. High glucose (HG 21mM)-treated cultured rat cardiomyocytes exhibited 
increased expression of NOX2. Results of their study further reports that activation of NOX2 
is related with the activation of Rac1GTP secondary pathway. Evidently, Rac1GTP activation 
is connected with the enhanced production of ROS and cell death through translocation of 
p47phox from cytoplasm to the plasma membrane. However, ROS production was 
significantly reduced in HG treated primary cultured rat cardiomyocytes co-incubated along 
with 1mM phlorizin. In conclusion, they proposed that the inhibition of SGLT1 in heart could 
be one of the probable mechanisms behind the reduced generation of ROS as it is the only 
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Moreover, similar kinds of results were also obtained in an in vitro experiment 
conducted on neonatal ventricular myocytes, where co-incubation of HG (30mM) for 24 hrs 
in insulin (10nM) pre-treated neonatal ventricular myocytes resulted in glycogen deposition. 
Increased expression of glycogen specific autophagy proteins has been reported in hearts of 
streptozotocin treated diabetic rats [53]. Evidently, increased glycogen accumulation has also 
been noticed in db/db diabetic mice [54]. Mutations in the PRKAG2 gene are one of the chief 
contributors in glycogen storage cardiomyopathy in human subjects [55]. An in vivo study, 
carried out on double transgenic mice, has reported that the transgenic knockdown of cardiac 
SGLT1 is associated with the attenuation of PRKAG2 gene mutation related cardiomyopathy. 
Double transgenic mouse (TG) (TGT400N/TGSGLT1-DOWN) was used in their 
experimental study, which was reproduced by allowing the transgenic mice (TG) over 
expressing human T400N mutant PRKAG2 cDNA (TGT400N) to cross over with the TG 
mice exhibiting particular knock down of cardiomyocyte selective RNA of SGLT1 
(TGSGLT1-DOWN). Data obtained from their study reveals that cardiac mass and glycogen 
accumulation was significantly reduced in TGT400N/TGSGLT1-DOWN mice indicating the 
potential role of SGLT1 in PRKAG2 gene related mutation. Salient findings obtained from 
their histopathological and echocardiographic studies further elucidate that 
TGT400N/TGSGLT1-DOWN mice were also capable of restoring structural and functional 
abnormalities and exerts beneficial effects on left ventricular function in comparison to the 
TG mice expressing SGLT1 i.e. (TGSGLT1-ON) (56). 
 
DRUG CANDIDATES FOR SGLT INHIBITION 
 In 1835, a dihydrochalcone glucoside, phlorizin (Fig 2.a) was isolated from the bark of apple 
tree, due to its bitter taste it was used as an antipyretic in patients suffering from malaria. In 
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glycosuria and later on it was established that phlorizin related effects are mediated through 
SGLT [57]. In early the 1970s, it was discovered that phlorizin acts on the renal proximal 
tubules playing an important role in restoring insulin sensitivity, and regulates glycaemic 
levels [58-62]. Phlorizin is a non-selective inhibitor of SGLT, but its poor pharmacokinetic 
profile and gastrointestinal side effects has limited its clinical utility [61,62]. Chemically, 
phlorizin is derived from an O-glycoside which undergoes rapid hydrolysis by the action of 
intestinal glycosidase [63]. Rapid hydrolysis of phlorizin has led to the development of novel 
phlorizin based analogues. These analogues are categorized by the type of glycoside from 
which they are derived (i) compounds derived from O-glycosides and (ii) those which are 
derived from C-glycoside (64). Table 2 presents the list of O and C glycosides. Compounds 
derived from C-glycoside hold better pharmacokinetic properties as they are resistant to the 
action of intestinal glycosidase. Currently, a majority of C-glycosides are under clinical trials 
while few got approved for their use in United States and Europe as an add-on therapy with 
marketed anti-hyperglycaemic agent [65]. Table 3 represents the list of recommended SGLT 
inhibitors approved by Diabetes Canada which are used in combination with marketed anti-
hyperglycaemic agents and table 4 presents the pharmacokinetic profile of the prominent 
SGLT inhibitors which are derived from C-glycosides. 
Presently, few SGLT2 inhibitors are approved for their commercial use in Europe, 
Canada, Japan and United States for treating T2DM [66]. Although available preparations are 
listed under inhibitors for SGLT2 but still they all possess varying degree of selectivity for 
SGLT1. For example, empagliflozin is 27,000 times more specific for SGLT2 in comparison 
to SGLT1 with a inhibitory concentration of IC50 = 3.1 nM (SGLT2), IC50 = 8,300 nM 
(SGLT1), similarly dapagliflozin, and canagliflozin are also highly specific for SGLT2 
compared to SGLT1. Inhibitory concentration of dapagliflozin for both the SGLT is IC50 = 
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achieved at maximal IC50 of 4.2 nM, however for attaining similar degree of inhibition for 
SGLT1 greater amount of inhibitor is required having an IC50 of 663 nM (67). Canagliflozin 
at a dose of 300 mg (more than the marketed dose) inhibits intestinal glucose absorption 
through inhibition of SGLT1 and stimulates the secretion of enteroendocrine cell (EEC) 
hormone in normoglycaemic adults (68). 
 
EFFICACY OF SGLT1 INHIBITORS IN PRECLINICAL AND CLINICAL STUDIES 
Sotagliflizon, a dual inhibitor of SGLT (SGLT1/SGLT2) possess a greater potency towards 
the inhibition of SGLT2. Per-oral (p.o) administration of sotaglifloizn significantly attenuates 
the increase in plasma glucose levels in T2D subjects maintained at high glucose diet [69, 
70]. Administration of sotagliflozin in T2D patients is coupled with the increased secretion of 
glucagon like peptide 1 (GLP-1) indicating its potent glucose lowering action with no reports 
of gastrointestinal side effects [70].  
At present, numerous clinical trials are being carried out on SGLT for the 
development of selective SGLT1 inhibitors [71-73]. Mizagliflozin (DSP-3235) and KGA-
2727 are two selective SGLT1 inhibitors which are under clinical trials; (Fig.2.b and Fig.2.c) 
[74]. Several lines of evidence indicate that the maximal glycaemic control can be achieved 
by administration of target specific pharmacologically active novel molecules [75,76]. For 
evaluating the role of SGLT1 inhibitor (KGA-2727), Shibazaki et al have investigated the 
effects of acute/chronic administration of KGA-2727 in Zucker fatty diabetic (ZDF) rats (a 
model for T2D) and in streptozotocin treated rats (a model for T1D) [77]. Administration of 
single dose of KGA 2727 in both the animal models caused significant reduction in intestinal 
glucose absorption and plasma glucose levels as demonstrated by oral glucose tolerance test 
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rats kept on fasting, caused significant reduction in blood glucose with an increase in GLP-1 
secretion although plasma glucose levels were reported to be decreased as demonstrated by 
OGTT. Improvement in structural abnormalities and morphological changes in pancreatic β-
cells were also observed in ZFD rats [77]. Dobbin and his colleagues reported that oral 
application of SGLT1 inhibitors prior to high glucose diet has significantly reduced the 
elevated blood glucose level [72]. Contrarily, when compared with the chronic treatment of 
sotagliflozin, chronic administration of KGA 2727 to ZFD rats has resulted in significantly 
increased levels of plasma insulin in OGTT. According to their study reduced excursions of 
blood glucose by SGLT1 inhibitors after uptake of glucose-rich food are due to the inhibition 
of glucose absorption. The effects of SGLT1 inhibitors on secretion of gastrointestinal 
hormones may be dependent on the composition of the ingested food. The effects may 
change during progression of the T2D [77]. Thus, SGLT1 inhibition represents a promising 
therapeutic strategy aimed at correcting diabetic complications through the inhibition of 
cardiac glucose uptake in myocytes.  
[Figure 2.a to 2.f] 
 
SGLT INHIBITORS UNDER CARDIOVASCULAR TRIALS  
 Several gliflozins such as empagliflozin, canagliflozin, dapagliflozin (Fig.2.d, Fig.2.e, 
Fig.2.f) are known to possess positive outcome on CV mortality. EMPA REG clinical trial 
for empagliflozin has reported 14% reduction in total incidences of non-fatal myocardial 
infarction and stroke in empagliflozin treated patients. Empagliflozin also caused a 35% 
reduction in hospitalization rate for heart failure although frequency for hospitalization of 
unstable angina cases remains unaltered. In secondary outcomes, remarkable decline of 38% 
has been observed in CV mortality rates and moreover deaths due to other causes have 










This article is protected by copyright. All rights reserved. 
between empagliflozin and placebo groups (7.8% vs. 8.2%) [78,79]. Despite of its listed 
beneficial effects, none of the changes have been observed in case of myocardial infarction 
(MI) and stroke in patients treated with empagliflozin compared to placebo. The exact 
mechanism of action behind the protective effect of SGLT inhibitors on CV function is still 
unknown. However, according to some reports obtained effects of SGLT inhibitors are 
related with the overall improvement in hemodynamic and renal functions [80, 81]. Some 
studies claim that modulation in cardiac energy substrate metabolism is the acting 
mechanistic pathway for SGLT [81]. Numerous trials are under pipeline on the major drug 
candidates of this class such as canagliflozin and dapagliflozin for evaluating its effect on CV 
function [82,83]. 
 Canagliflozin Cardiovascular Assessment Study (CANVAS) was a randomized, 
placebo controlled single blinded, parallel study.  A total of 10,142 T2D patients were 
enrolled in the presented study with (n = 5,795) in canagliflozin arm and (n = 4,347) in 
placebo arm. Patients were treated daily with 100 mg and 300 mg daily doses of 
canagliflozin. T2D patients of ≥30 years of age having history of atherosclerotic cardiac 
disease and are highly susceptible for CV risk were recruited in this study. Another age group 
of patients having ≥50 years of age with high-density lipoprotein cholesterol concentration 
(<38.7 mg/dl) were considered suitable for the CANVAS. In canagliflozin arm incidence of 
MI, stroke and CV mortality has been reported in 26.9 patients out of 1,000 patients 
compared to the 31.5 patients out of 1,000 patients in placebo arm. Albuminuria levels were 
also found to be reduced in 89.4 patients compared to the 128.7 patients out of 1,000 
participants, p value < 0.05 was considered as statistically significant. Results obtained from 
the CANVAS trial have shown beneficial effects on T2D patients presentable with a history 
of CVD [83]. Hence, it can be interpreted that canagliflozin could be one of the best suitable 
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clinical trials are also being carried out on dapagliflozin for evaluating the risk benefit ratio 
for its use in T2D subject which are prone to CV risk [84]. 
Dapagliflozin Effect on Cardiovascular Events (DECLARE-TIMI158) (ClinicalTrials.gov 
Identifier: NCT01730534) [84]. Based on the findings of this trial, the use of dapagliflozin at 
5 mg and 10 mg doses has been approved by European Medical agency (EMA), Food drug 
administration (FDA), and Pharmaceuticals and Medical Devices Agency. Japan (PMDA). 
Dapagliflozin Effect on Symptoms and Biomarkers in Diabetes Patients with Heart Failure 
(DEFINE-HF) (ClinicalTrials.gov Identifier: NCT02653482) [85], presently participants are 
being enrolled for this study, it is sponsored by Saint Luke's Health System. In addition to 
this, Effect of Dapagliflozin on the Incidence of Worsening Heart Failure (DAPA-HF) is 
another study to be conducted for dapagliflozin. DAPA-HF is sponsored by AstraZeneca 
(ClinicalTrials.gov Identifier: NCT03036124) [86]. Above mentioned are the major clinical 
trials for assessing the efficacy of dapagliflozin against CV disease events [84-87]. Results 
from CANVAS, DECLARE and EMPA REG in future will help the scientists and health care 
providers to conclude that whether the positive CV outcomes achieved are confined only to 
the empagliflozin drug of this class or they are associated with the class effect. Table 5 
briefly explains the current status of gliflozins. 
 
POTENTIAL SIDE EFFECTS OF INHIBITION OR DOWN REGULATION OF 
SGLT1/SGLT2 
Potential side effects in the small intestine and kidney 
Glucose galactose malabsorption is often linked with the use of SGLT1 inhibitors acting in 
the small intestine. Gastrointestinal side effects can be minimized by using reversible SGLT1 
inhibitors which partially blocks SGLT1 and by prescribing suitable dosage that could be 
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reported that RS1 protein, encoding RSC1A1 gene causes upregulation of SGLT1 at post-
transcriptional level and RS1derived peptides containing motifs of hRS1 such as QCP, QSP 
possess the ability to cause inhibition of SGLT1 expression at post-transcriptional level at 
low glucose concentrations. Regardless of this information, further studies on RS1 peptides 
are still needed to be carried out to investigate its role in selective inhibition of SGLT1. 
Moreover with use of these peptides, side effects of glucose and galactose malabsorption 
were also not observed [88]. In case of enteric inflammation caused due to bacterial infection, 
up-regulation of SGLT1 is known to impart protective effect. Possible mechanism behind the 
observed effects could be associated with the increased uptake, followed by subsequent 
increase in glucose and galactose concentrations in the small intestine [89-91]. Evidently, 
SGLT1 also plays an important role in ameliorating the gastrointestinal mucositis when 
treated with the cytostatic agents. Interestingly, gastrointestinal mucositis was also found to 
be inhibited in wild type mice expressing SGLT++ on treatment with glucose analog 
BLF501, however no inhibition was observed in SGLT—knockdown mice [92]. 
 
Genital mycotic infections (GMI) 
Data obtained from several clinical studies have presented the increased risk of GMIs and 
urinary tract infections (UTIs) linked with the use of SGLT inhibitors [93-100]. Increased 
incidence of GMIs and UTIs has been reported with the use of dapagliflozin and 
canagliflozin in female population when compared to male population [101-102]. In one 
study, investigators have found that four month chronic treatment of canagliflozin has 
presented the risk of GMI in 10.4% female and 4.2 % male patients compared to the dummy 
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Majority of the GMI cases (99% approx) can be treated with the marketed antifungal drugs. 
The chances of getting affected by UTI are approximately 5 % in all the subjects who are on 
glifozin therapy. Recent meta-analysis conducted on gliflozins presented an increased risk of 
42% for UTIs with a confidence interval of 1.06 to 1.90, whereas risk for GMIs is 
predominant in females with an occurrence rate of 5 to 10%. [104]. A higher occurrence rate 
of UTIs and GMIs in gliflozin users is attributed to the consistent and marked glycosuria 
which promotes the growth of pathogenic microbes. Interestingly, inhibition of SGLT1 is 
known to exert immunological effect playing an essential role in prevention and protection of 
sepsis in gut [86]. The Canagliflozin trial, having both male and female participants, has 
indicated that the male subjects are at greater vulnerability of developing genital infections 
such as balanitis/balanoposthitis [97,105], while the females were more prone to candidiasis 
infection such as vulvo-vaginal candidiasis, vulvitis, vulvovaginal mycotic infection, vulvo-
vaginitis [101, 105-111]. Higher rates of UTIs (2.9% to 13.3%) compared to placebo/dummy 
medication have also been noted in the T2D patients taking one or more medication from 
standard treatment regimen such as pioglitazone or sitagliptin, irrespective of the use of any 
of the inhibitor of SGLT, less than 1% cases are linked with the concurrent organ damage or 
withdrawal of drug therapy [101, 105-107, 109, 111]. Most of the GMIs and UTIs occur 
within the first year of a start of the drug therapy, with a relapse rate of less than 3 %. A 
newer meta-analysis for dapagliflozin, comprising data obtained from 12 randomized placebo 
controlled trials was carried out to assess the vulnerability of UTIs, with their most common 
forms such as dysuria or cystitis. The collected data was represented in the form of 
percentage, but this study fails to provide the mean statistical differences existing between the 
specific groups. Three doses of dapagliflozin 2.5 mg, 5 mg, and 10 mg with n =814, n=1145 
and n=1193 patients and n=1393 patients in placebo arm were used in the study [112]. Higher 
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dapagliflozin dose groups compared to the placebo arm with an incidence rate of 4.2% and 
4.5% in case of 2.5mg dose of dapagliflozin. For clinical assessment of UTIs, urine samples 
were collected from all the patients who have been found symptomatic for the occurrence of 
UTIs. Routine culture of urine samples was performed to determine the vulnerability of UTIs 
in dapagliflozin treated patients, patients treated with 5 mg and 10 mg doses of dapagliflozin 
represents the more positive trend for getting affected by UTIs [101, 112]. Treatment with 
canagliflozin has not shown any significant differences in the mean percentage risk for 
bacterial infections affecting the lower urinary tract. Evidently, 8.7% females are at increased 
susceptibility of having lower urinary tract bacterial infections, compared to placebo with a 
percentage risk of 7.7% [113]. However, comparatively lower rate of incidence has been 
observed in male subjects (1.4%) compared to placebo (0.6%) [114]. Further, reported UTIs 
are not fatal and can be treated with the marketed antibiotics.  
 
Effects on bone biomarkers and fracture 
Higher incidence of bone fractures have been prevalent in T2D subjects, however the 
possible causes of bone fractures, changes in bone mineral density and bone biomarkers 
remains poorly understood. These incidences are further strengthened by the concomitant use 
of other anti-diabetic agents such as thiazolidinediones which are commonly used for treating 
T2D [115]. Hence, assessing the risk benefit ratio and effect of SGLT on bone mineral 
density and biomarkers is of considerable importance. Clinical studies have reported 
significant increase in beta-CTx (17.1% to 24.9%), a known bone resorption marker with a 
modest decrease in procollagen type 1 N-terminal propeptide (P1 NP) (−5.7% to −6.9%), an 
important marker for bone formation in the canagliflozin treated group [116, 117]. Similar 
kind of modifications in bone density markers were also observed in the patients taking 
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with no changes in P1 NP [115]. Despite several changes in bone biomarkers, none of the 
incidence has been reported for bone fracture in gliflozin users [114]. Several evidences 
elucidate that pioglitazone use is linked with the greater risk (5.1%) of  bone fractures 
compared to placebo (2.5%). However, the  use of canagliflozin for treating T2D possess an 
advantage over pioglitazone as its use is associated with negligible bone demineralization as 
illustrated by Dual-energy X-ray absorptiometry (DEXA) [117]. Another study assessed that 
the use of canagliflozin is linked with an overall increase of up to 2.5% and 2.3% bone 
fracture incidence at 100 mg and 300 mg dose compared to placebo [118]. According to 
European medical agency (EMA), no incidence of dapagliflozin induced bone 
demineralization has been reported in elderly patients or in renal compromised patients (≥60 
to <90 mL/min/1.73 m2), although some cases of bone fractures have been related well with 
the use of dapagliflozin in renal compromised patients with an average risk of 4.8% and 9.4% 
in 5 mg and 10 mg treated individuals (EMA [homepage on the Internet] Forxiga 
(Dapagliflozin) [119,120]. A phase III, randomized, double-blind, placebo controlled, 102- 
week (24-weeks for multicentred study and 78 weeks of extended patient blind study) study 
demonstrates the zero percent change in bone biomarkers when compared with placebo. It 
also recommends the use of dapagliflozin as a safer add-on therapy to metformin for treating 
T2D. Moreover, similar results were also reported for canagliflozin use. However, 
canagliflozin was administered only for a limited period of 26 weeks [121].  
 In case of emapagliflozin minimal number of evidences has been reported for bone fracture 
compared to placebo, with no effects on bone mineral density even after the chronic 
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Malignancies   
Studies on clinical subjects have indicated that SGLT1 plays an important role in mediating 
glucose uptake in cancerous cells. However, the precise mechanism by which it contributes to 
carcinogenesis is poorly understood [124]. Recently, it has been reported that inhibition of 
SGLT1 directly exerts deteriorating effects on the treatment of cancer.  Increased risk of 
bladder and breast cancer has been observed in dapagliflozin trial. Data obtained from meta-
analysis of dapagliflozin indicates the increased risk of bladder and breast cancer when 
compared with the placebo [119,121,124]. According to the reports published by FDA, 
10/6045 bladder cancer cases were noted in dapagliflozin group and 1/3512 in control group, 
with an overall occurrence rate of 6.11% [118]. The underlying mechanism behind the 
increased risk of cancer growth with the use of dapagliflozin could be based on the following 
assumptions (i) increased excretion of glucose in urine, promoting proliferation of malignant 
cells and (ii) urinary tract infections associated with the use of SGLT, as there continuous use 
may cause irritation in bladder epithelium [125]. Further use of dapagliflozin alone and in 




Enhanced glycosuria offers a promising therapeutic approach for treating hyperglycaemia and 
its related cardiovascular complications. Efficacy of SGLT inhibitors for treating diabetes has 
been proven clinically, it has been elucidated that SGLT inhibitors can also be used for 
treating obesity. Further, reports suggest that it can be used in conjunction with other 
available anti-diabetic agents and insulin to enhance its efficacy. Recent reports suggest that 
oral application of SGLT inhibitors also helps in reducing blood pressure and promotes 
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improvement in glomerular function and damage, results from chronic studies are still 
awaited. To date, very few data is available, concerned with the use of dual SGLT1/SGLT2 
inhibitors and much more safety data from clinical trials is still awaited for proving its 
protective role in diabetes related cardiovascular complications and for the development of 
specific SGLT1 inhibitors. 
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FIGURE LEGENDS 
Figure.1. Role of SGLT inhibitors in progression of diabetic cardiomyopathy. In 
addition to free fatty acids glucose acts as a cardiac fuel and is involved in energy production. 
Under normal conditions basal glucose uptake was regulated by glucose transporter 1 
(GLUT1), whereas glucose transporter 4 (GLUT4) is responsible for insulin induced glucose 
uptake. Both GLUT1 and GLUT4 belong to the major class of facilitative transporters. It has 
been suggested that under diabetic condition, GLUT4 expression is getting significantly 
reduced however this decrease is compensated by the upregulation of sodium glucose 
transporter 1 (SGLT1) which is possibly involved in impairment of cardiac energy substrate 
metabolism playing a chief role in cardiac damage. Along with this, SGLT1 upregulation has 
also been correlated well with the glycogen accumulation, activation of NADPH oxidase 
(NOX2) and production of reactive oxygen species (ROS).  
 













Table 1 Localization and expression of SGLT1 in human and rat under diabetic 
condition. 
Localization Species Expression under 
diabetic condition 
Reference 
Heart Rat (capillaries), human Up-regulated in both  (123,124) 
Small intestine Rat , human Up-regulated in both  (123, 125) 
Kidney Rat , human Up-regulated in rat            (47, 128) 
Trachea Human Unknown (46) 
Pancreatic alpha 
cells 
Human Unknown  (4) 
Liver Human Unknown (43) 




Rat, human Unchanged in rat, 





Human Unknown (45) 
Skeletal muscle Rat Unknown (131) 
Prostate Human Unknown (45) 
Cervix Human Unknown (45) 











Table 2 SGLT inhibitors derived from O glycosides and C glycosides. * SGLT1 selective. 
O-glycosides Drawback Reference 
T-1095 Extensive hepatic 



















C-glycosides Drawback Reference 
Dapaglifozin 
(BMS-512148) 






























Urinary tract infections (141) 
Ipragliflozin 
(ASP-1941) 
Urinary tract infections (141) 
Luseogliflozin 
(TS-071) 
Urinary tract infections (141) 
Ertugliflozin 
(PF-04971729) 
Urinary tract infections (140) 
Sotagliflozin 
(LX-4211) 
Urinary tract infections (142) 
*Mizagliflozin 
(DSP-3235) 




















Table 3 SGLT inhibitors as add on therapy agents with other anti-hyperglycaemic 
conditions. 
SGLT inhibitor 








Add on to MET, SU/ Add on to 
MET+ SU 






5 mg 10 mg Yes Yes Yes 
Empagliflozin 
(Jardiance®) 
10 mg 25 mg Yes Yes and also with PIO Yes 
Canagliflozin 
(Invokana®) 
100 mg 300 mg Yes Yes Yes 
 

















Table.4. Pharmacokinetic profile of the prominent SGLT inhibitors which are derived 
from C-glycosides. 































Development phase Dose (mg/kg) Registered cardiovascular trial 
Empagliflozin Approved by European 
medicine agency (2014/05), 
Food drug administration 
(2014/08) 
10, 25  
(EMPA-REG-OUTCOMETM) 
(Empagliflozin) Cardiovascular 
Outcome Event Trial in Type 2 




Canagliflozin Approved by   European 
medicine agency (2013/11), 
Food drug administration   















Source of information: homepages of the FDA, EMA, PMDA, (148-153) 
(www.clinicaltrials.gov). Abbreviations: PMDA, Pharmaceuticals and Medical Devices 
Agency. Japan. 
 
(2013/03),  NCT01032629 
 
 
Dapagliflozin Approved by   European 
medicine agency (2012/11),  
Food drug administration  
(2014/01), PMDA (2014/03) 
5, 10 mg  
DECLARE TIMI58 





Luseogliflozin Approved by PMDA (2014/03) 2.5, 5 NCT02528019 
Tofogliflozin Approved by PMDA (2014/3) 20 Not applicable 
Ipragliflozin Approved by PMDA (2014/01) 25, 50 Not applicable 
GSK-1614235 Phase I 1, 5, 20 
(0.25 to 40) 
NCT01607385 
BI44847 Phase I 100, 400, 800 Not applicable 
LX4211 Phase II  NCT01742208 
EGT0001474 Phase I 25, 75, 150 NCT00924053 
ISIS-SGLT2Rx Phase I 50, 100, 200, 
400 
NCT00836225 












Development phase Dose (mg/kg) Registered cardiovascular trial 
Empagliflozin Approved by European 
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Food drug administration 
(2014/08) 
10, 25  
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(Empagliflozin) Cardiovascular 
Outcome Event Trial in Type 2 




Canagliflozin Approved by   European 
medicine agency (2013/11), 
Food drug administration   
(2013/03),  







Dapagliflozin Approved by   European 
medicine agency (2012/11),  
Food drug administration  
(2014/01), PMDA (2014/03) 
5, 10 mg  
DECLARE TIMI58 





Luseogliflozin Approved by PMDA (2014/03) 2.5, 5 NCT02528019 
Tofogliflozin Approved by PMDA (2014/3) 20 Not applicable 
Ipragliflozin Approved by PMDA (2014/01) 25, 50 Not applicable 
GSK-1614235 Phase I 1, 5, 20 
(0.25 to 40) 
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BI44847 Phase I 100, 400, 800 Not applicable 
LX4211 Phase II  NCT01742208 
EGT0001474 Phase I 25, 75, 150 NCT00924053 
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